newsfilter
← Latest News
GlobeNewswire·

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal in Cohort P with